Statements (34)
Predicate | Object |
---|---|
gptkbp:instanceOf |
gptkb:drug
MEK inhibitor |
gptkbp:administeredBy |
oral route
|
gptkbp:approvedBy |
gptkb:European_Medicines_Agency
|
gptkbp:ATCCode |
L01EE03
|
gptkbp:brand |
gptkb:Mektovi
|
gptkbp:CASNumber |
606143-52-6
|
gptkbp:chemicalFormula |
C17H15BrF2N4O3
|
gptkbp:compatibleWith |
gptkb:U.S._Food_and_Drug_Administration
|
gptkbp:contraindication |
pregnancy
lactation |
gptkbp:developedBy |
gptkb:Array_BioPharma
|
https://www.w3.org/2000/01/rdf-schema#label |
Binimetinib
|
gptkbp:legalStatus |
prescription only
|
gptkbp:marketedAs |
gptkb:Novartis
|
gptkbp:mechanismOfAction |
inhibits MEK1/2 enzymes
|
gptkbp:molecularWeight |
415.2 g/mol
|
gptkbp:PubChem_CID |
gptkb:CHEMBL1873475
50908541 |
gptkbp:sideEffect |
nausea
vomiting diarrhea fatigue rash increased creatine phosphokinase |
gptkbp:target |
gptkb:MEK1
gptkb:MEK2 |
gptkbp:UNII |
Q1ZXA2J1XK
|
gptkbp:usedFor |
treatment of melanoma
treatment of colorectal cancer treatment of non-small cell lung cancer |
gptkbp:bfsParent |
gptkb:MAP2K1_gene
gptkb:MEK1/2 |
gptkbp:bfsLayer |
7
|